<p>Migraine is a highly disabling neurological condition that requires effective preventive treatment options. We developed CT-132, a digital therapeutic that delivers clinically validated cognitive behavioral therapeutic interventions, as an adjunct to existing migraine therapies. We evaluated CT-132 for the preventive treatment of migraine in two randomized controlled trials, and this report is an integrated analysis of the two similarly designed trials: ReMMi-D (<i>n</i> = 568), which included patients on prescription migraine medications (not migraine-specific), and ReMMiD-C, a study (<i>n</i> = 110), in patients taking migraine-specific medications (i.e., CGRPi). Pooled data (<i>N</i> = 678) from these post-hoc analyses demonstrated that CT-132 significantly reduced monthly migraine days (LS mean difference, –0.86 days; <i>p</i> = 0.003) and improved secondary outcomes, had high engagement, and no device-related safety concerns. This data supports that CT-132 is an effective and safe digital therapeutic when used as an adjunct to medication for patients with episodic migraine. ReMMi-D: ClinicalTrials.gov NCT05853900 <a href="https://clinicaltrials.gov/study/NCT05853900?term=NCT05853900&amp;rank=1">https://clinicaltrials.gov/study/NCT05853900?term=NCT05853900&amp;rank=1</a>. REMMiD-C: ClinicalTrials.gov NCT06004388 <a href="https://clinicaltrials.gov/study/NCT06004388?term=NCT06004388&amp;rank=1">https://clinicaltrials.gov/study/NCT06004388?term=NCT06004388&amp;rank=1</a></p>